Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma Phase I/II Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a prospective, single-center phase I/II study, with the purpose of evaluating the efficiency of golidocitinib combined with chidamide in patients with systemically-treated cutaneous T-cell lymphoma. The primary endpoint of the phase I study was to determine the recommended phase II dose (RP2D), while the primary endpoint of the phase II study was the objective response rate (ORR). Secondary endpoints included the complete response (CR) rate, progression-free survival (PFS), duration of response (DOR), overall survival (OS), and safety profile.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem chłoniaka skóry typu T
- •Mierzalny nowotwór, stadium IB-IVB
- •Choroba oporna na lub powróciła po co najmniej jednym wcześniejszym leczeniu systemowym
- •Ogólny stan zdrowia oceniany jako 0-2 (pacjent może być aktywny)
- •Prawidłowa liczba białych krwinek, płytek krwi i hemoglobiny
- •Prawidłowa praca serca, wątroby i nerek
- •Prawidłowe saturacje tlenu powyżej 93%
✗ Disqualifies
- •Zawał serca, niestabilna dławica piersiowa lub arytmia w ciągu ostatnich 6 miesięcy
- •Niekontrolowana aktywna infekcja
- •Aktywne zapalenie wątroby typu B lub C
- •Gruźlica
- •Ciąża lub karmienie piersią
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Peking Union Medical College Hospital
Beijing, China
Trial contact
Wei Zhang
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.